2024 Q3 Form 10-Q Financial Statement

#000149315224035352 Filed on September 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q1 2023 Q4
Revenue $349.0K $312.4K
YoY Change -52.88% -48.56%
Cost Of Revenue $233.3K $333.5K
YoY Change -34.94% -73.77%
Gross Profit $115.7K -$21.17K
YoY Change -69.71% -96.81%
Gross Profit Margin 33.15% -6.78%
Selling, General & Admin $1.328M $3.107M
YoY Change -62.93% 393.21%
% of Gross Profit 1148.31%
Research & Development $272.0K $362.7K
YoY Change -37.56% 43.45%
% of Gross Profit 235.13%
Depreciation & Amortization $75.83K $28.11K
YoY Change 169.76% -45.73%
% of Gross Profit 65.55%
Operating Expenses $1.601M $3.470M
YoY Change -60.18% 293.05%
Operating Profit -$1.485M -$3.491M
YoY Change -59.19% 125.68%
Interest Expense -$5.381M -$1.485M
YoY Change -238.19% -62.66%
% of Operating Profit
Other Income/Expense, Net -$6.590M -$268.6K
YoY Change 104.65% -3169.49%
Pretax Income -$8.074M -$9.904M
YoY Change 17.74% 122.14%
Income Tax
% Of Pretax Income
Net Earnings -$8.074M -$10.54M
YoY Change 17.74% 115.45%
Net Earnings / Revenue -2313.59% -3373.1%
Basic Earnings Per Share -$0.22
Diluted Earnings Per Share -$0.22 -$0.33
COMMON SHARES
Basic Shares Outstanding 37.38M shares 39.81M shares 21.73M shares
Diluted Shares Outstanding 39.81M shares

Balance Sheet

Concept 2024 Q3 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.220K $81.28K
YoY Change -98.65% 2000.26%
Cash & Equivalents $3.220K $81.28K
Short-Term Investments
Other Short-Term Assets $212.5K $222.6K
YoY Change -17.48% -13.55%
Inventory $596.9K $304.9K
Prepaid Expenses
Receivables $144.6K $151.2K
Other Receivables $0.00 $0.00
Total Short-Term Assets $957.3K $760.1K
YoY Change -38.43% -38.86%
LONG-TERM ASSETS
Property, Plant & Equipment $78.45K $84.93K
YoY Change -21.45% -17.82%
Goodwill $4.728M
YoY Change
Intangibles $0.00
YoY Change -100.0%
Long-Term Investments $66.03K $61.88K
YoY Change -7.91% -2.77%
Other Assets
YoY Change
Total Long-Term Assets $6.034M $289.6K
YoY Change 815.59% -62.21%
TOTAL ASSETS
Total Short-Term Assets $957.3K $760.1K
Total Long-Term Assets $6.034M $289.6K
Total Assets $6.992M $1.050M
YoY Change 215.81% -47.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.439M $1.320M
YoY Change 217.15% 107.21%
Accrued Expenses $3.922M $3.119M
YoY Change 40.7% 11.11%
Deferred Revenue
YoY Change
Short-Term Debt $26.35M $22.60M
YoY Change 34.74% 12.43%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.57M $33.58M
YoY Change 29.55% -2.41%
LONG-TERM LIABILITIES
Long-Term Debt $161.2K $161.9K
YoY Change -1.62% 7.91%
Other Long-Term Liabilities $387.8K $65.52K
YoY Change 299.0% -53.78%
Total Long-Term Liabilities $549.0K $227.4K
YoY Change 110.32% -22.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.57M $33.58M
Total Long-Term Liabilities $549.0K $227.4K
Total Liabilities $45.12M $33.80M
YoY Change 30.16% -2.57%
SHAREHOLDERS EQUITY
Retained Earnings -$177.7M -$169.0M
YoY Change 25.95% 26.3%
Common Stock $470.8K $353.7K
YoY Change 160.63% 158.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$38.13M -$32.75M
YoY Change
Total Liabilities & Shareholders Equity $6.992M $1.050M
YoY Change 215.81% -47.77%

Cashflow Statement

Concept 2024 Q3 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$8.074M -$10.54M
YoY Change 17.74% 115.45%
Depreciation, Depletion And Amortization $75.83K $28.11K
YoY Change 169.76% -45.73%
Cash From Operating Activities -$1.860M -$1.132M
YoY Change 340.43% -20.65%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $1.782M 1.208M
YoY Change 169.77% 0.7%
NET CHANGE
Cash From Operating Activities -$1.860M -1.132M
Cash From Investing Activities 0.000
Cash From Financing Activities $1.782M 1.208M
Net Change In Cash -$78.06K 76.01K
YoY Change -133.19% -133.48%
FREE CASH FLOW
Cash From Operating Activities -$1.860M -$1.132M
Capital Expenditures $0.00
Free Cash Flow -$1.860M -$1.132M
YoY Change 337.33% -20.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
usd
CY2023Q4 PBIO Convertible Preferred Share Liability One
ConvertiblePreferredShareLiabilityOne
usd
CY2023Q4 PBIO Options Payable
OptionsPayable
usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 PBIO Gain On Loan Forgiveness
GainOnLoanForgiveness
usd
CY2023Q1 PBIO Preferred Stock Issued For Interest
PreferredStockIssuedForInterest
usd
CY2023Q1 PBIO Preferred Stock For Services
PreferredStockForServices
usd
CY2023Q1 PBIO Preferred Stock Issued Debt Extensions
PreferredStockIssuedDebtExtensions
usd
CY2023Q1 PBIO Investment Banker Fees
InvestmentBankerFees
usd
CY2023Q1 PBIO Increase Decrease In Exchange Account
IncreaseDecreaseInExchangeAccount
usd
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
CY2023Q1 PBIO Preferred Stock Issue With Debt
PreferredStockIssueWithDebt
usd
CY2023Q1 PBIO Conversion Of Common Stock For Preferred Stock
ConversionOfCommonStockForPreferredStock
usd
CY2024Q1 PBIO Conversion Of Debt And Interest Into Common Stock
ConversionOfDebtAndInterestIntoCommonStock
usd
CY2023Q1 PBIO Preferred Stock And Options Issued Acquisition
PreferredStockAndOptionsIssuedAcquisition
usd
CY2023Q1 PBIO Initial Recognition Of Rou Assets And Liabilities
InitialRecognitionOfRouAssetsAndLiabilities
usd
CY2023 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
CY2024Q1 PBIO Stock Issued During Period Value Conversion Of Convertible Securities Conversion Of Preferred Stock For Common Stock
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock
usd
CY2024Q1 PBIO Stock Issued During Period Value Conversion Of Common Stock To Preferred Stock
StockIssuedDuringPeriodValueConversionOfCommonStockToPreferredStock
usd
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2024Q1 PBIO Ub Exchange Account
UbExchangeAccount
1181 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
596404 usd
CY2024Q1 PBIO Convertible Preferred Share Liability
ConvertiblePreferredShareLiability
1725000 usd
CY2024Q1 PBIO Convertible Preferred Share Liability One
ConvertiblePreferredShareLiabilityOne
1066800 usd
CY2024Q1 PBIO Options Payable
OptionsPayable
2210060 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
44569315 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33576120 usd
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
161182 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
161864 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
379661 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
60961 usd
CY2024Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
8167 usd
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4560 usd
CY2024Q1 us-gaap Liabilities
Liabilities
45118325 usd
CY2023Q4 us-gaap Liabilities
Liabilities
33803505 usd
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
103 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
102 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47073892 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47073892 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35367663 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35367663 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
470808 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
353677 usd
CY2024Q1 PBIO Warrants To Acquire Common Stock
WarrantsToAcquireCommonStock
35684321 usd
CY2023Q4 PBIO Warrants To Acquire Common Stock
WarrantsToAcquireCommonStock
35684321 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103453087 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
100236710 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-177735115 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-169028639 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-38126796 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-32753829 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6991529 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1049676 usd
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
233310 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
358628 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
272023 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
435646 usd
CY2024Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
130173 usd
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
226015 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1198309 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3358056 usd
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
1833815 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
4378345 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1484558 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3637745 usd
CY2024Q1 us-gaap Interest Expense Other
InterestExpenseOther
5384991 usd
CY2023Q1 us-gaap Interest Expense Other
InterestExpenseOther
3893686 usd
CY2024Q1 us-gaap Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
4155 usd
CY2023Q1 us-gaap Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
8061 usd
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1211511 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
659277 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2482 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6259 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6589865 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3220089 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8074423 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6857834 usd
CY2024Q1 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
632053 usd
CY2023Q1 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
431807 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8706476 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7289641 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39811524 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39811524 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15839373 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15839373 shares
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8074423 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6857834 usd
CY2023Q1 PBIO Gain On Loan Forgiveness
GainOnLoanForgiveness
659277 usd
CY2024Q1 PBIO Noncash Lease Expense
NoncashLeaseExpense
48561 usd
CY2023Q1 PBIO Noncash Lease Expense
NoncashLeaseExpense
90279 usd
CY2024Q1 PBIO Common Stock And Warrants Issued For Interest
CommonStockAndWarrantsIssuedForInterest
1136790 usd
CY2023Q1 PBIO Common Stock And Warrants Issued For Interest
CommonStockAndWarrantsIssuedForInterest
1705234 usd
CY2024Q1 PBIO Preferred Stock Issued For Interest
PreferredStockIssuedForInterest
892343 usd
CY2024Q1 PBIO Preferred Stock For Services
PreferredStockForServices
67500 usd
CY2024Q1 PBIO Preferred Stock Issued Debt Extensions
PreferredStockIssuedDebtExtensions
1160880 usd
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
75827 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
28114 usd
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1571926 usd
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-615007 usd
CY2024Q1 PBIO Common Stock Issued For Debt Extension
CommonStockIssuedForDebtExtension
-110310 usd
CY2023Q1 PBIO Common Stock Issued For Debt Extension
CommonStockIssuedForDebtExtension
-1029939 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
240292 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1430244 usd
CY2024Q1 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
4155 usd
CY2023Q1 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
8061 usd
CY2024Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
11100 usd
CY2023Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1480944 usd
CY2024Q1 PBIO Investment Banker Fees
InvestmentBankerFees
210060 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-11718 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
96780 usd
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-58968 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-20338 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-11279 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
25 usd
CY2024Q1 PBIO Increase Decrease In Exchange Account
IncreaseDecreaseInExchangeAccount
1181 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-225930 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
131729 usd
CY2024Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-14125 usd
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
101299 usd
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-14464 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-127014 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
867164 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
693653 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1859560 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-422211 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100000 usd
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
81111 usd
CY2024Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2056289 usd
CY2023Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2520000 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Other Long Term Debt
ProceedsFromIssuanceOfOtherLongTermDebt
94371 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Other Long Term Debt
ProceedsFromIssuanceOfOtherLongTermDebt
654681 usd
CY2024Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
97052 usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
88200 usd
CY2024Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
394229 usd
CY2023Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
1628474 usd
CY2024Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
8682 usd
CY2023Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
99000 usd
CY2024Q1 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
63300 usd
CY2023Q1 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
1056149 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1781501 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
660369 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-78059 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
235158 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
81279 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3865 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3220 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
239023 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
324763 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
534872 usd
CY2024Q1 us-gaap Stock Issued1
StockIssued1
140455 usd
CY2023Q1 us-gaap Stock Issued1
StockIssued1
1087751 usd
CY2024Q1 PBIO Preferred Stock Issue With Debt
PreferredStockIssueWithDebt
260000 usd
CY2024Q1 PBIO Common Stock Issued In Lieu Of Cash For Dividend
CommonStockIssuedInLieuOfCashForDividend
38838 usd
CY2023Q1 PBIO Common Stock Issued In Lieu Of Cash For Dividend
CommonStockIssuedInLieuOfCashForDividend
102435 usd
CY2024Q1 PBIO Noncash Preferred Stock Dividends
NoncashPreferredStockDividends
632053 usd
CY2023Q1 PBIO Noncash Preferred Stock Dividends
NoncashPreferredStockDividends
431807 usd
CY2024Q1 PBIO Conversion Of Preferred Stock For Common Stock
ConversionOfPreferredStockForCommonStock
69550 usd
CY2023Q1 PBIO Conversion Of Preferred Stock For Common Stock
ConversionOfPreferredStockForCommonStock
4935 usd
CY2024Q1 PBIO Conversion Of Common Stock For Preferred Stock
ConversionOfCommonStockForPreferredStock
8750 usd
CY2023Q1 PBIO Conversion Of Debt And Interest Into Common Stock
ConversionOfDebtAndInterestIntoCommonStock
509033 usd
CY2024Q1 PBIO Preferred Stock And Options Issued Acquisition
PreferredStockAndOptionsIssuedAcquisition
5959834 usd
CY2024Q1 PBIO Initial Recognition Of Rou Assets And Liabilities
InitialRecognitionOfRouAssetsAndLiabilities
471155 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-32686371 usd
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81111 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1430244 usd
CY2023 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
431807 usd
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1419335 usd
CY2023 PBIO Issuance Of Common Stock Warrants For Services
IssuanceOfCommonStockWarrantsForServices
61609 usd
CY2023 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
509033 usd
CY2023 PBIO Issuance Of Common Stock For Dividends Paidinkind
IssuanceOfCommonStockForDividendsPaidinkind
102435 usd
CY2023 PBIO Issuance Of Common Stock For Interest Paidinkind
IssuanceOfCommonStockForInterestPaidinkind
1705234 usd
CY2023 PBIO Stock Issued During Period Value Common Stock Issued For Debt Extension
StockIssuedDuringPeriodValueCommonStockIssuedForDebtExtension
1029939 usd
CY2023 PBIO Stock Issued During Period Value Stock Issued With Debt
StockIssuedDuringPeriodValueStockIssuedWithDebt
1087751 usd
CY2023 PBIO Stock Issued During Period Value Sale Of Common Stock For Cash
StockIssuedDuringPeriodValueSaleOfCommonStockForCash
100000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-6857834 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-32449321 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-32753829 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-32753829 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
240292 usd
CY2024Q1 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
431709 usd
CY2024Q1 PBIO Stock Issued During Period Value Series Cc Stock Dividend
StockIssuedDuringPeriodValueSeriesCCStockDividend
200344 usd
CY2024Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
140455 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
110310 usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
11100 usd
CY2024Q1 PBIO Issuance Of Common Stock For Interest Paidinkind
IssuanceOfCommonStockForInterestPaidinkind
1136790 usd
CY2024Q1 PBIO Issuance Of Common Stock For Dividends Paidinkind
IssuanceOfCommonStockForDividendsPaidinkind
38838 usd
CY2024Q1 PBIO Stock Issuance Preferred Stock For Services Values
StockIssuancePreferredStockForServicesValues
67500 usd
CY2024Q1 PBIO Preferred Stock For Debt Extension
PreferredStockForDebtExtension
520880 usd
CY2024Q1 PBIO Preferred Stock Issued With Debt
PreferredStockIssuedWithDebt
260000 usd
CY2024Q1 PBIO Preferred Stock For Interest Paidinkind
PreferredStockForInterestPaidinkind
807343 usd
CY2024Q1 PBIO Preferred Stock Issue For Ub Acquisition
PreferredStockIssueForUbAcquisition
1 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8074423 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-38126796 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-38126796 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_843_eus-gaap--UseOfEstimates_zZitMTXl6uU9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zCww6G1VEfgc">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. In addition, estimates were made in projecting future cash flows to quantify impairment of assets, fair value of share based awards and investments in equity securities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
596404 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
332875 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
263529 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
596404 usd
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
349000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
741000 usd
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
349000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
741000 usd
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
349000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
741000 usd
CY2024Q1 us-gaap Accounts Receivable Billed For Long Term Contracts Or Programs
AccountsReceivableBilledForLongTermContractsOrPrograms
145000 usd
CY2023Q4 us-gaap Accounts Receivable Billed For Long Term Contracts Or Programs
AccountsReceivableBilledForLongTermContractsOrPrograms
151000 usd
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
242000 usd
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
34000 usd
CY2024Q1 PBIO Extended Warranty Service
ExtendedWarrantyService
242000 usd
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zbEWOJjdqxu3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zZKAF4P3LEx5">Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Credit Risk</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--FairValueConcentrationOfRiskTextBlock_zqYMicoW1Oc8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of total revenues during the three months ended March 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zRktLEixLHC3" style="display: none">Schedule of Customer Concentration Risk Percentage</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Top Five Customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20240331__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zeCSFIiVmbPa" style="width: 16%; text-align: right" title="Concentration credit risk percentage">48</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQftjV6uCfe" style="width: 16%; text-align: right" title="Concentration credit risk percentage">64</td><td style="width: 1%; text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of March 31, 2024 and December 31, 2023. The Top Five Customers category may include federal agency receivable balances if applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Top Five Customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20240331__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z5VRO4BsIzGk" style="width: 16%; text-align: right" title="Concentration credit risk percentage">100</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zy9wmQBRtZ8e" style="width: 16%; text-align: right" title="Concentration credit risk percentage">96</td><td style="width: 1%; text-align: left">%</td></tr> </table> <p id="xdx_8A9_znPtiymfNR4f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8706476 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7289641 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39811524 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39811524 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15839373 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15839373 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
62301281 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35909806 shares
CY2024Q1 PBIO Forfeiture Rate
ForfeitureRate
0.05 pure
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
240292 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1430244 usd
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
240292 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1430244 usd
CY2024Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
66031 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
61876 usd
CY2024Q1 PBIO Business Combination Recognized Identifiable Fair Value If Options Issued To Finders
BusinessCombinationRecognizedIdentifiableFairValueIfOptionsIssuedToFinders
210060 usd
CY2024Q1 PBIO Business Combination Expected Time To Maturity
BusinessCombinationExpectedTimeToMaturity
P2Y6M
CY2024Q1 PBIO Business Combination Annual Risk Free Rate
BusinessCombinationAnnualRiskFreeRate
0.0418 pure
CY2024Q1 PBIO Business Combination Annualized Volatility
BusinessCombinationAnnualizedVolatility
1.03 pure
CY2024Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
4727976 usd
CY2024Q1 PBIO Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Trade Payables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradePayables
734000 usd
CY2024Q1 PBIO Business Acquisition Of Stockholders Received
BusinessAcquisitionOfStockholdersReceived
127 shares
CY2024Q1 PBIO Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Preferred Stock
BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesPreferredStock
2540000 shares
CY2024Q1 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
4000000 usd
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
180908 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
211852 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
203753 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
158054 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
164133 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
41036 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
959736 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
375189 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
584547 usd
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
48561 usd
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
90279 usd
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M2D
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
565409 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
142815 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
204886 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
66895 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
379661 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
60961 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
584547 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
127856 usd
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
32997 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
37810 usd
CY2024Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
21737 usd
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
20850 usd
CY2024Q1 us-gaap Lease Cost
LeaseCost
54734 usd
CY2023Q1 us-gaap Lease Cost
LeaseCost
58660 usd
CY2024Q1 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
113100 usd
CY2024Q1 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
394229 usd
CY2024Q1 us-gaap Debt Instrument Maturity Date Description
DebtInstrumentMaturityDateDescription
March, 2020 to March, 2025
CY2024Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
16800000 usd
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
23920432 usd
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
21329312 usd
CY2024Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
403060 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
645471 usd
CY2024Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
23517372 usd
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
20683841 usd
CY2024Q1 us-gaap Debt Instrument Convertible Stock Price Trigger
DebtInstrumentConvertibleStockPriceTrigger
2.50
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
2.50
CY2024Q1 PBIO Debt Default Convertible Conversion Ratio
DebtDefaultConvertibleConversionRatio
0.75 pure
CY2024Q1 us-gaap Debt Instrument Convertible Stock Price Trigger
DebtInstrumentConvertibleStockPriceTrigger
2.50
CY2024Q1 PBIO Debt Default Convertible Conversion Ratio
DebtDefaultConvertibleConversionRatio
0.75 pure
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
2.50
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price Increase
DebtInstrumentConvertibleConversionPriceIncrease
2.50
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
2.50
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
2.50
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price Increase
DebtInstrumentConvertibleConversionPriceIncrease
2.50
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
2.50
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price Decrease
DebtInstrumentConvertibleConversionPriceDecrease
2.50
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
2.50
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price Increase
DebtInstrumentConvertibleConversionPriceIncrease
2.50
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
2.50
CY2024Q1 us-gaap Debt Default Longterm Debt Amount
DebtDefaultLongtermDebtAmount
1 usd
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
2.50
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
2.50
CY2024Q1 PBIO Percentage Of Price Rate
PercentageOfPriceRate
0.10 pure
CY2024Q1 PBIO Convertible Lesser Per Share
ConvertibleLesserPerShare
2.5
CY2024Q1 PBIO Convertible Lesser Discount Percent
ConvertibleLesserDiscountPercent
0.25 pure
CY2024Q1 us-gaap Debt Conversion Original Debt Interest Rate Of Debt
DebtConversionOriginalDebtInterestRateOfDebt
0.35 pure
CY2024Q1 PBIO Convertible Lesser Per Share
ConvertibleLesserPerShare
2.50
CY2024Q1 PBIO Convertible Lesser Discount Percent
ConvertibleLesserDiscountPercent
0.25 pure
CY2024Q1 us-gaap Debt Instrument Convertible Threshold Trading Days
DebtInstrumentConvertibleThresholdTradingDays
5 integer
CY2024Q1 PBIO Convertible Lesser Per Share
ConvertibleLesserPerShare
2.50
CY2024Q1 us-gaap Debt Conversion Description
DebtConversionDescription
Some notes can be converted at $2.50 through fixed rate expiration dates; thereafter lesser of (1) lowest trading price during the prior 25 days of the note or 65% of the lowest price during the 25 days prior to the conversion. Notes can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold by PBI at a price lower than $2.50/share. Notes can be voluntary converted at lower of lower of (i) $2.5/share and (ii) purchase Price of stock sold by PBIO at a price lower than $2.50/share that is not an Excluded Event in the Series AA Deal Documents. Notes can be converted at lower of lower of (i) $2.50 or (ii) the conversion price of the Series AA Preferred Stock as adjusted. Notes can be converted at lower of (i) $2.50 or (ii) the purchase price of stock by Series AA Holders.
CY2024Q1 us-gaap Other Borrowings
OtherBorrowings
2313930 usd
CY2023Q4 us-gaap Other Borrowings
OtherBorrowings
1426026 usd
CY2024Q1 us-gaap Other Long Term Debt
OtherLongTermDebt
161182 usd
CY2023Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
161864 usd
CY2024Q1 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
2152748 usd
CY2023Q4 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
1264162 usd
CY2024Q1 PBIO Convertible Loan
ConvertibleLoan
794215 usd
CY2024Q1 us-gaap Debt Instrument Annual Principal Payment
DebtInstrumentAnnualPrincipalPayment
700000 usd
CY2024Q1 us-gaap Notes Payable
NotesPayable
150000 usd
CY2024Q1 PBIO Accrued Interest Rate Percent
AccruedInterestRatePercent
0.0375 pure
CY2024Q1 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
731 usd
CY2024Q1 us-gaap Principal Transactions Revenue
PrincipalTransactionsRevenue
682 usd
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
103 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
102 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20628305 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
18625326 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
803750 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
21432055 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
19148779 shares
CY2024Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
5724504 shares
CY2024Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P8Y5M8D
CY2024Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
0.26
CY2024Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3571425 shares
CY2024Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P7Y10M13D
CY2024Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
0.25
CY2024Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
140455 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
110310 usd
CY2024Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
70000 shares
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
11100 usd
CY2024Q1 PBIO Issuance Of Common Stock For Interest Paidinkind
IssuanceOfCommonStockForInterestPaidinkind
1136790 usd
CY2024Q1 PBIO Issuance Of Common Stock For Dividends Paidinkind
IssuanceOfCommonStockForDividendsPaidinkind
38838 usd

Files In Submission

Name View Source Status
0001493152-24-035352-index-headers.html Edgar Link pending
0001493152-24-035352-index.html Edgar Link pending
0001493152-24-035352.txt Edgar Link pending
0001493152-24-035352-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
pbio-20240331.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pbio-20240331_lab.xml Edgar Link unprocessable
pbio-20240331_def.xml Edgar Link unprocessable
pbio-20240331_cal.xml Edgar Link unprocessable
pbio-20240331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending